NEU1 and sialidosis type I: In this study we wanted to test and compare the effects of conventional and unconventional therapeutics, i.e., a recombinant form of human PPCA (rhPPCA), and pharmacological and dietary compounds, on the residual activity of NEU1 mutant proteins in a cohort of 12 primary fibroblast strains isolated from type I sialidosis patients and in mice with residual Neu1 activity, mimicking sialidosis type I. This is in an effort to identify alternative therapeutic approaches that could improve the quality of life of patients with this condition.